Gimeracil (103766-25-2) is a dihydropyrimidine dehydrogenase (DPD) inhibitor.? DPD is involved in the degradation of pyrimidine-based chemotherapeutic drugs such as 5-fluorouracil (5-FU).? Gimeracil is used along with 5-FU or Tegafur to prolong circulating concentrations of the drugs.1,2? Gimeracil has also been shown to act as a radiosensitizer via inhibition of homologous recombination in the repair of DNA double strand breaks.3
Gimeracil is an inhibitor of dihydropyrimidine dehydrogenase, which inhibits the early step in homologous recombination for double strand breaks repair.
Antitumor agent. A potent inhibitor of dihydropyrimidine dehydrogenase (DPD)
Gimeracil is an antitumor agent. Gimeracil is a potent inhibitor of dihydropyrimidine dehydrogenase (DPD).
ChEBI: Gimeracil is an organic molecular entity.
1) Diasio (1999)?Clinical implications of dihydropyrimidine dehydrogenase inhibition; Oncology(Williston Park),?13?17
2) Kobayakawa and Kojima (2011),?Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies; Onco. Targets Ther.,?4?193
3) Sakata?et al.?(2011),?Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination; Cancer Sci.,?102?1712
